Eloxx brings in first $5mm of $24mm Series C
Israeli biotech Eloxx Pharmaceuticals Ltd. (focused on genetic diseases caused by nonsense mutations) raised $5mm from Quark Venture and GF Securities (through their Global Health Science Fund) as the first part of a potential $24mm Series C round led by Pontifax.
- Antisense, Oligonucleotides
- Drug Discovery Technologies
- Large Molecule
- Synthesis Technologies, Production Processes
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.